181 related articles for article (PubMed ID: 22028770)
1. APOE genotype-function relationship: evidence of -491 A/T promoter polymorphism modifying transcription control but not type 2 diabetes risk.
Geng H; Law PP; Ng MC; Li T; Liang LY; Ge TF; Wong KB; Liang C; Ma RC; So WY; Chan JC; Ho YY
PLoS One; 2011; 6(10):e24669. PubMed ID: 22028770
[TBL] [Abstract][Full Text] [Related]
2. The algorithm for Alzheimer risk assessment based on APOE promoter polymorphisms.
Limon-Sztencel A; Lipska-Ziętkiewicz BS; Chmara M; Wasag B; Bidzan L; Godlewska BR; Limon J
Alzheimers Res Ther; 2016 May; 8(1):19. PubMed ID: 27193889
[TBL] [Abstract][Full Text] [Related]
3. Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene as risk factors for Alzheimer's disease.
Bratosiewicz-Wasik J; Liberski PP; Peplonska B; Styczynska M; Smolen-Dzirba J; Cycon M; Wasik TJ
Neurosci Lett; 2018 Sep; 684():86-90. PubMed ID: 29990559
[TBL] [Abstract][Full Text] [Related]
4. Effect of the APOE-491A/T promoter polymorphism on apolipoprotein E levels and risk of Alzheimer disease: The Rotterdam Study.
Roks G; Cruts M; Houwing-Duistermaat JJ; Dermaut B; Serneels S; Havekes LM; Hofman A; Breteler MM; Van Broeckhoven C; van Duijn CM
Am J Med Genet; 2002 Jul; 114(5):570-3. PubMed ID: 12116196
[TBL] [Abstract][Full Text] [Related]
5. The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism.
Town T; Paris D; Fallin D; Duara R; Barker W; Gold M; Crawford F; Mullan M
Neurosci Lett; 1998 Aug; 252(2):95-8. PubMed ID: 9756330
[TBL] [Abstract][Full Text] [Related]
6. Promoter polymorphism (-491A/T) in the APOE gene of Finnish Alzheimer's disease patients and control individuals.
Helisalmi S; Hiltunen M; Valonen P; Mannermaa A; Koivisto AM; Lehtovirta M; Ryynänen M; Soininen H
J Neurol; 1999 Sep; 246(9):821-4. PubMed ID: 10525981
[TBL] [Abstract][Full Text] [Related]
7. Association between ε2/3/4, promoter polymorphism (-491A/T, -427T/C, and -219T/G) at the apolipoprotein E gene, and mental retardation in children from an iodine deficiency area, China.
Li J; Zhang F; Wang Y; Wang Y; Qin W; Xing Q; Qian X; Guo T; Gao X; He L; Gao J
Biomed Res Int; 2014; 2014():236702. PubMed ID: 24790992
[TBL] [Abstract][Full Text] [Related]
8. Relations of APOE promoter polymorphisms to LDL cholesterol and markers of subclinical atherosclerosis in young adults.
Viiri LE; Raitakari OT; Huhtala H; Kähönen M; Rontu R; Juonala M; Hutri-Kähönen N; Marniemi J; Viikari JS; Karhunen PJ; Lehtimäki T
J Lipid Res; 2006 Jun; 47(6):1298-306. PubMed ID: 16528057
[TBL] [Abstract][Full Text] [Related]
9. Interactions of functional apolipoprotein E gene promoter polymorphisms with smoking on aortic atherosclerosis.
Viiri LE; Viiri KM; Ilveskoski E; Huhtala H; Mäki M; Tienari PJ; Perola M; Lehtimäki T; Karhunen PJ
Circ Cardiovasc Genet; 2008 Dec; 1(2):107-16. PubMed ID: 20031552
[TBL] [Abstract][Full Text] [Related]
10. The complex interaction between APOE promoter and AD: an Italian case-control study.
Bizzarro A; Seripa D; Acciarri A; Matera MG; Pilotto A; Tiziano FD; Brahe C; Masullo C
Eur J Hum Genet; 2009 Jul; 17(7):938-45. PubMed ID: 19172988
[TBL] [Abstract][Full Text] [Related]
11. The effects of an APOE promoter polymorphism on human cortical morphology during nondemented aging.
Chen Y; Li P; Gu B; Liu Z; Li X; Evans AC; Gong G; Zhang Z
J Neurosci; 2015 Jan; 35(4):1423-31. PubMed ID: 25632120
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E promoter polymorphisms (-491A/T and -427T/C) and Alzheimer's disease: no evidence of association in the Irish population.
Lynch CA; Brazil J; Cullen B; Coakley D; Gill M; Lawlor BA; Hawi Z
Ir J Med Sci; 2008 Mar; 177(1):29-33. PubMed ID: 18057979
[TBL] [Abstract][Full Text] [Related]
13. Association of apolipoprotein E promoter polymorphisms with bone structural traits is modified by dietary saturated fat intake - the Cardiovascular Risk in Young Finns study.
Tolonen S; Mikkilä V; Laaksonen M; Sievänen H; Mononen N; Hernesniemi J; Vehkalahti K; Viikari J; Raitakari O; Kähönen M; Lehtimäki T
Bone; 2011 May; 48(5):1058-65. PubMed ID: 21266206
[TBL] [Abstract][Full Text] [Related]
14. Effect of APOE genotype and promoter polymorphism on risk of Alzheimer's disease.
Wang JC; Kwon JM; Shah P; Morris JC; Goate A
Neurology; 2000 Dec; 55(11):1644-9. PubMed ID: 11113217
[TBL] [Abstract][Full Text] [Related]
15. Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene.
Artiga MJ; Bullido MJ; Frank A; Sastre I; Recuero M; García MA; Lendon CL; Han SW; Morris JC; Vázquez J; Goate A; Valdivieso F
Hum Mol Genet; 1998 Nov; 7(12):1887-92. PubMed ID: 9811931
[TBL] [Abstract][Full Text] [Related]
16. APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss.
Laws SM; Clarnette RM; Taddei K; Martins G; Paton A; Hallmayer J; Almeida OP; Groth DM; Gandy SE; Förstl H; Martins RN
Mol Psychiatry; 2002; 7(7):768-75. PubMed ID: 12192621
[TBL] [Abstract][Full Text] [Related]
17. Haplogroup analysis of the risk associated with APOE promoter polymorphisms (-219T/G, -491A/T and -427T/C) in Colombian Alzheimer's disease patients.
Parra-Bonilla G; Arboleda G; Yunis J; Solano E; Pardo R; Arango G; Hedmont D; Arboleda H
Neurosci Lett; 2003 Oct; 349(3):159-62. PubMed ID: 12951193
[TBL] [Abstract][Full Text] [Related]
18. APOE rs405509 polymorphism and Parkinson's disease risk in the Chinese population.
Huang M; Wang Y; Wang L; Chen B; Wang X; Hu Y
Neurosci Lett; 2020 Sep; 736():135256. PubMed ID: 32682842
[TBL] [Abstract][Full Text] [Related]
19. No association between the APOE gene and autism.
Raiford KL; Shao Y; Allen IC; Martin ER; Menold MM; Wright HH; Abramson RK; Worley G; DeLong GR; Vance JM; Cuccaro ML; Gilbert JR; Pericak-Vance MA
Am J Med Genet B Neuropsychiatr Genet; 2004 Feb; 125B(1):57-60. PubMed ID: 14755445
[TBL] [Abstract][Full Text] [Related]
20. Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E.
Laws SM; Hone E; Taddei K; Harper C; Dean B; McClean C; Masters C; Lautenschlager N; Gandy SE; Martins RN
Mol Psychiatry; 2002; 7(8):886-90. PubMed ID: 12232782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
